




Chapman & Hall/CRC Biostatistics Series

Design and Analysis of Bioavailability and Bioequivalence Studies

Third Edition



Shein-Chung Chow

Jen-pei Liu



CRC Press

Taylor & Francis Group

A CHAPMAN & HALL BOOK

R96
C552
E-3

Chapman & Hall/CRC Biostatistics Series

Design and Analysis of Bioavailability and Bioequivalence Studies

Third Edition



Shein-Chung Chow

Jen-pei Liu



E2009000201



CRC Press

Taylor & Francis Group

Boca Raton London New York

CRC Press is an imprint of the
Taylor & Francis Group, an **informa** business

A CHAPMAN & HALL BOOK

Chapman & Hall/CRC
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742

© 2009 by Taylor & Francis Group, LLC
Chapman & Hall/CRC is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works
Printed in the United States of America on acid-free paper
10 9 8 7 6 5 4 3 2 1

International Standard Book Number-13: 978-1-58488-668-6 (Hardcover)

This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

Visit the Taylor & Francis Web site at
<http://www.taylorandfrancis.com>

and the CRC Press Web site at
<http://www.crcpress.com>

Design and Analysis of Bioavailability and Bioequivalence Studies

Third Edition

Chapman & Hall/CRC Biostatistics Series

Editor-in-Chief

Shein-Chung Chow, Ph.D.

Professor

Department of Biostatistics and Bioinformatics

Duke University School of Medicine

Durham, North Carolina, U.S.A.

Series Editors

Byron Jones

Senior Director

Statistical Research and Consulting Centre

(IPC 193)

Pfizer Global Research and Development

Sandwich, Kent, UK

Jen-pei Liu

Professor

Division of Biometry

Department of Agronomy

National Taiwan University

Taipei, Taiwan

Karl E. Peace

Georgia Cancer Coalition

Distinguished Cancer Scholar

Senior Research Scientist and

Professor of Biostatistics

Jiann-Ping Hsu College of Public Health

Georgia Southern University

Statesboro, GA

Bruce W. Turnbull

Professor

School of Operations Research

and Industrial Engineering

Cornell University

Ithaca, NY

Chapman & Hall/CRC Biostatistics Series

Published Titles

1. *Design and Analysis of Animal Studies in Pharmaceutical Development*, Shein-Chung Chow and Jen-pei Liu
2. *Basic Statistics and Pharmaceutical Statistical Applications*, James E. De Muth
3. *Design and Analysis of Bioavailability and Bioequivalence Studies*,
Second Edition, Revised and Expanded, Shein-Chung Chow and Jen-pei Liu
4. *Meta-Analysis in Medicine and Health Policy*, Dalene K. Stangl and Donald A. Berry
5. *Generalized Linear Models: A Bayesian Perspective*, Dipak K. Dey,
Sujit K. Ghosh, and Bani K. Mallick
6. *Difference Equations with Public Health Applications*, Lemuel A. Moyé
and Asha Seth Kapadia
7. *Medical Biostatistics*, Abhaya Indrayan and Sanjeev B. Sarmukaddam
8. *Statistical Methods for Clinical Trials*, Mark X. Norleans
9. *Causal Analysis in Biomedicine and Epidemiology: Based on Minimal
Sufficient Causation*, Mikel Aickin
10. *Statistics in Drug Research: Methodologies and Recent Developments*,
Shein-Chung Chow and Jun Shao
11. *Sample Size Calculations in Clinical Research*, Shein-Chung Chow, Jun Shao, and Hansheng
Wang
12. *Applied Statistical Design for the Researcher*, Daryl S. Paulson
13. *Advances in Clinical Trial Biostatistics*, Nancy L. Geller
14. *Statistics in the Pharmaceutical Industry, Third Edition*, Ralph Buncher
and Jia-Yeong Tsay
15. *DNA Microarrays and Related Genomics Techniques: Design, Analysis, and Interpretation of
Experiments*, David B. Allison, Grier P. Page, T. Mark Beasley, and Jode W. Edwards
16. *Basic Statistics and Pharmaceutical Statistical Applications, Second Edition*,
James E. De Muth
17. *Adaptive Design Methods in Clinical Trials*, Shein-Chung Chow and Mark Chang
18. *Handbook of Regression and Modeling: Applications for the Clinical and Pharmaceutical
Industries*, Daryl S. Paulson
19. *Statistical Design and Analysis of Stability Studies*, Shein-Chung Chow
20. *Sample Size Calculations in Clinical Research, Second Edition*, Shein-Chung Chow,
Jun Shao, and Hansheng Wang
21. *Elementary Bayesian Biostatistics*, Lemuel A. Moyé
22. *Adaptive Design Theory and Implementation Using SAS and R*, Mark Chang
23. *Computational Pharmacokinetics*, Anders Källén
24. *Computational Methods in Biomedical Research*, Ravindra Khattree and
Dayanand N. Naik
25. *Medical Biostatistics, Second Edition*, A. Indrayan
26. *DNA Methylation Microarrays: Experimental Design and Statistical Analysis*,
Sun-Chong Wang and Arturas Petronis
27. *Design and Analysis of Bioavailability and Bioequivalence Studies, Third Edition*,
Shein-Chung Chow and Jen-pei Liu

Preface

As the first decade of the twenty-first century draws to an end, the arena of bioavailability and bioequivalence has generated a lot of scientific, statistical, and regulatory activities and issues from the pharmaceutical industry, health authorities, as well as academia, since the publication of the second edition of our book in 2000. In particular, a series of regulatory guidelines or guidances were issued by different health authorities in the world. In January 2001, the U.S. Food and Drug Administration (FDA) issued the guidance on *Statistical Approaches to Establishing Bioequivalence*. Six months later, in July 2001, the European Agency for the Evaluation of Medicinal Products (EMA) issued the *Note for Guidance on the Investigation of Bioavailability and Bioequivalence*. In March 2003, the U.S. FDA released the guidance on *Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations*. Later, the World Health Organization, in 2005, issued the draft revision of the guidelines on *Multisource (Generic) Pharmaceutical Products: Registration Requirements to Establish Interchangeability*. On the other hand, tremendous opportunities as well as challenges still lie ahead for bioavailability and bioequivalence in the twenty-first century because of breakthroughs in biotechnology and methodological research in medicine, pharmacokinetics, and statistics. In response to the challenges, upon the invitation of Professor R.B.D'Agostino, one of the co-editors of *Statistics in Medicine*, we were invited as guest editors for a special issue of 13 papers on individual bioequivalence that was published on October 30, 2000. In addition, the U.S. FDA issued a document on *Critical Path Opportunities for Generic Products* on May 1, 2007 to address emerging challenges and opportunities for generic drug products. The issues on the regulations and scientific issues of biosimilar products or follow-on biologics still remain unresolved. Consequently, there is an urgent need for the third edition of this book to provide a complete and overall presentation of the latest development of activities and results in bioavailability and bioequivalence on regulatory requirements, scientific and practical issues, and statistical methodology.

The third edition is different from the first and second editions in four aspects. First, we have revised and updated each section to reflect recent developments in statistical methodology in the design and analysis of bioavailability and bioequivalence studies. For example, the third edition provides a complete update of the status of regulations on bioavailability and bioequivalence, especially, the guidelines issued by the U.S. FDA, EMA, and WHO. Second, the third edition is expanded to 20 chapters, 4 chapters more than the second edition and 8 chapters more than

the first. The third edition includes four new chapters as well as some new sections to present a complete account of the new developments in bioavailability and bioequivalence studies. The four new chapters include "Population Pharmacokinetics" (Chapter 17), "Other Pharmacokinetic Studies" (Chapter 18), "Review of Regulatory Guidances on Bioequivalence" (Chapter 19), and "Frequently Asked Questions and Future Challenges" (Chapter 20). Third, to deliver an effective presentation of the material, we modified the configurations of the 20 chapters into 5 parts: "Preliminaries," "Average Bioequivalence," "Population and Individual Bioequivalence," "*In Vitro* and Alternative Evaluation of Bioequivalence," and "Other Bioequivalence Studies." Part I, "Preliminaries", describes the regulatory history of bioavailability and bioequivalence, design of bioavailability studies, and statistical inference for the standard 2×2 crossover design. Part II, "Average Bioequivalence," reviews the methods for evaluation of average bioequivalence, power and sample size determination, transformation and assessment of intra- and inter-subject variabilities, outlier detection, and higher-order designs for evaluation of average bioequivalence. Part III, "Population and Individual Bioequivalence," gives an update of the methods for the design and analysis of population and individual bioequivalence. Part IV, "*In Vitro* and Alternative Evaluation of Bioequivalence," includes assessment of average bioequivalence with negligible plasma levels, *in vitro* bioequivalence studies, and *in vitro* dissolution profile comparison. Part V, "Other Bioequivalence Studies," consists of meta-analysis for bioequivalence review, population pharmacokinetics, other pharmacokinetic studies, review of regulatory guidance, and future challenges. Finally, the third edition has 120 new references from the bioavailability and bioequivalence literature.

Similar to the first two editions, the third edition is also entirely devoted to the design and analysis of bioavailability and bioequivalence studies. It covers all of the statistical issues that may occur in the various stages of design and data analysis in bioavailability and bioequivalence studies. We strongly believe that this new, updated and much expanded third edition not only is an extremely useful reference book for pharmaceutical scientists and researchers, regulatory reviewers, clinicians, and biostatisticians in the academia, regulatory agencies, and pharmaceutical industry but also serves as an advanced textbook for graduate courses dealing with the topics of bioavailability and bioequivalence in the areas of pharmacokinetics, clinical pharmacology, and biostatistics. It is also our intent that this book will serve as a bridge among the pharmaceutical industry, government regulatory agencies, and academia.

Although the information, material, and presentation configuration of the third edition are different from the first two editions, the third edition still focuses on concepts rather than technical details. The mathematics and statistics dealt in the book are still fundamental. We have received many positive and constructive feedbacks and comments from scientists and researchers in academia, regulatory agencies, including the FDA, and pharmaceutical industry. Therefore, we have maintained our intuitive writing style as well as the emphasis on concepts through numerous examples and illustrations.

We would like to thank Jessica Vakili and David Grubbs of Taylor & Francis for their administrative assistance and support. We are deeply indebted to the Duke

University School of Medicine (especially, Rob Califf, MD, Robert Harrington, MD, Ralph Corey, MD, John McHutchison, MD, and Wesley Burks, MD) and the National Taiwan University for their encouragement and support. We also want to express our sincere gratitude to many pharmaceutical scientists, researchers, and biostatisticians for their feedbacks, support, and encouragement. Chow wishes to thank his fiancée Annpey Pong, PhD, for her constant encouragement and support during the preparation of this edition. Liu wishes to express his appreciation to his wife, Professor Wei-Chu Chie, MD, PhD, and daughter, Angela, for their patience, endurance, understanding, and support during the preparation of this edition.

Finally, we are fully responsible for any errors remaining in the book. The views expressed in this book are those of the authors and are not necessarily those of the Duke University School of Medicine, the National Taiwan University, or the National Health Research Institutes of Taiwan.

Shein-Chung Chow
Jen-pei Liu

Authors

Shein-Chung Chow, PhD is currently a professor in the Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina. Before joining Duke University, he was the director of the Taiwan Cooperative Oncology Group Statistical Center and the executive director of National Clinical Trial Network Coordination Center of Taiwan. Dr. Chow has also held various positions in the pharmaceutical industry including vice president. He has worked in the areas of biostatistics and data management, and as a medical writer at Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts. He had also been executive director, statistics and clinical programming, at Covance, Inc. Princeton, New Jersey; director and department head at Bristol-Myers Squibb, Plainsboro, New Jersey; senior statistician at Parke-Davis Pharmaceutical Division, Warner-Lambert Company, Ann Arbor, Michigan; and research statistician at Wyeth-Ayerst Laboratories, Rouses Point, New York. Through these positions, Dr. Chow provided technical supervision and guidance to project teams on statistical issues and made presentations for partners, regulatory agencies, or scientific bodies, defending the appropriateness of statistical methods used in clinical trial design, data analyses, and the validity of reported statistical inferences. Dr. Chow has identified best statistical and data management practices, organized and led working parties for the development of statistical design, analyses, and presentation applications, and has participated on many data safety monitoring boards.

Dr. Chow's professional activities include playing key roles in many professional organizations such as officer, board of directors member, advisory committee member, and executive committee member. He has served as program chair, session chair/moderator, panelist, and instructor/faculty at many professional conferences, symposia, workshops, tutorials, and short courses. He is the editor-in-chief of the *Journal of Biopharmaceutical Statistics*. Dr. Chow is also the editor-in-chief of the CRC Press biostatistics series. He was elected fellow of the American Statistical Association in 1995 and was elected member of the International Statistical Institute in 1999. He was the recipient of the DIA Outstanding Service Award (1996), the ICSA Extraordinary Achievement Award (1996), and the Chapter Service Recognition Award of the American Statistical Association (1998). Dr. Chow was scientific advisor to the Department of Health, Taiwan, Republic of China during 1999–2001 and from 2006 till date. Dr. Chow was president of the International Chinese Statistical Association, chair of the advisory committee on Chinese pharmaceutical affairs, and a member of the advisory committee on statistics of the DIA.

Dr. Chow has authored/co-authored over 170 methodology papers and 14 books, which include *Advanced Linear Models, Design and Analysis of Bioavailability and Bioequivalence Studies* (first and second editions), *Statistical Design and Analysis in Pharmaceutical Science, Design and Analysis of Clinical Trials* (first and second editions), *Design and Analysis of Animal Studies in Pharmaceutical Development, Encyclopedia of Biopharmaceutical Statistics* (first and second editions), *Sample Size Calculations in Clinical Research, Adaptive Design Methods in Clinical Trials*, and *Statistical Design and Analysis of Stability Studies*.

Dr. Chow received a BS in mathematics from the National Taiwan University, Taipei, Taiwan and a PhD in Statistics from the University of Wisconsin, Madison.

Jen-pei Liu, PhD is currently the director of Statistical Education Center, National Taiwan University, the director of Consulting Center for Statistics and Bioinformatics, National Taiwan University, and a Professor of Statistics, Division of Biometry, Department of Agronomy, National Taiwan University, Taipei, Taiwan. Professor Liu is a clinical biostatistician with more than 20 years experience, and has been involved with all phases of clinical trials in a wide spectrum of therapeutic areas. He also has extensive publications. His publication includes five reference books in statistical methods for the biopharmaceutical industry (Marcel Dekker) and *Design and Analysis of Clinical Trials* (co-authored with S.C. Chow; John Wiley & Sons), over 120 articles in peer-reviewed statistical journals, and over 20 invited book chapters in the *Encyclopedia of Biostatistics* and *Encyclopedia of Biopharmaceutical Statistics*. His papers were cited in the 2001 FDA guidance on *Statistical Approach to Establishing Bioequivalence* and in the 2005 WHO guideline on multisource drug products. He is an associate editor for the *Journal of Biopharmaceutical Statistics*, an associate editor for the *Taiwan Journal of Public Health* (since January 2002), and a member of the advisory committee on *Statistics in Biosciences* (since January 2008). He is one of the editors for the CRC Press biostatistics series. He serves as a referee for many international statistics journals. Currently, he is on the Drug Consultation Committee, the Committee for Medical Devices, and the Committee for the Chinese Drug and Pharmacy, all for the Department of Health, Taiwan. Dr. Liu received his BS in agronomy and MS in biometry from the National Taiwan University, Taipei, Taiwan and his MS and PhD in Statistics from the University of Kentucky, Lexington.

Contents

Preface	xvii
Authors	xxi
I Preliminaries	1
1 Introduction	3
1.1 History of Bioavailability Studies.....	3
1.2 Formulations and Routes of Administration.....	8
1.3 Pharmacokinetic Parameters	9
1.4 Clinically Important Differences.....	15
1.5 Assessment of Bioequivalence	16
1.6 Decision Rules and Regulatory Aspects.....	20
1.6.1 Average Bioequivalence	20
1.6.1.1 75/75 Rule	20
1.6.1.2 80/20 Rule	21
1.6.1.3 ± 20 Rule.....	21
1.6.1.4 80/125 Rule	21
1.6.2 Population and Individual Bioequivalence	22
1.6.2.1 Moment-Based Criteria	22
1.6.2.2 Probability-Based Criteria.....	23
1.7 Statistical Considerations	24
1.7.1 AUC Calculation.....	24
1.7.2 Model Selection and Normality Assumptions	24
1.7.3 Inter- and Intra-Subject Variabilities.....	25
1.7.4 Interval Hypothesis and Two One-Sided Tests	26
1.7.5 Outlier Detection.....	27
1.7.6 Subject-by-Formulation Interaction	27
1.7.7 Meta-Analysis of Bioequivalence.....	28
1.7.8 Other Issues.....	28
1.8 Aims and Structure of the Book	29
2 Design of Bioavailability Studies	31
2.1 Introduction.....	31
2.2 Study Objective.....	32

2.2.1	Bioequivalence Studies	32
2.2.2	Dose Proportionality Studies	33
2.2.3	Steady-State Studies	33
2.2.4	Variability and Interchangeability	33
2.3	Basis Design Considerations	33
2.3.1	Experimental Design	34
2.3.2	Randomization	34
2.3.3	Sampling Time Intervals	35
2.3.4	Drug Elimination Period	35
2.3.5	Number of Subjects	35
2.4	Parallel Design	35
2.5	Crossover Design	37
2.5.1	Introduction	37
2.5.2	Washout and Carryover Effects	37
2.5.3	Statistical Model and Linear Contrast	38
2.5.4	Crossover Designs for Two Formulations	39
2.5.5	Crossover Designs for Three or More Formulations	45
2.6	Balanced Incomplete Block Design	49
2.7	Selection of Design	51
3	Statistical Inferences for Effects from a Standard 2×2 Crossover Design	55
3.1	Introduction	55
3.2	Carryover Effects	57
3.3	Direct Drug Effect	59
3.4	Period Effect	64
3.5	Analysis of Variance	66
3.6	Example	70
3.6.1	Carryover Effects	73
3.6.2	Direct Drug Effect	73
3.6.3	Period Effect	74
3.6.4	Analysis of Variance	75
3.6.5	Test for Inter-Subject Variability	75
II	Average Bioequivalence	77
4	Statistical Methods for Average Bioequivalence	79
4.1	Introduction	79
4.2	Confidence Interval Approach	82
4.2.1	Classic (Shortest) Confidence Interval	82
4.2.2	Westlake's Symmetric Confidence Interval	86
4.2.3	Confidence Interval Based on Fieller's Theorem	88
4.2.4	Chow and Shao's Joint Confidence Region	92
4.3	Methods of Interval Hypotheses Testing	97
4.3.1	Interval Hypotheses	97

4.3.2	Schuirmann's Two One-Sided Tests Procedure	98
4.3.3	Anderson and Hauck's Test	99
4.4	Bayesian Methods	102
4.4.1	Rodda and Davis Method	103
4.4.2	Mandallaz and Mau's Method	106
4.5	Nonparametric Methods	109
4.5.1	Wilcoxon–Mann–Whitney Two One-Sided Tests Procedure	110
4.5.2	Distribution-Free Confidence Interval Based on the Hodges–Lehmann Estimator	115
4.5.3	Bootstrap Confidence Interval	117
4.6	Discussion and Other Alternatives	119
4.6.1	Discussion	119
4.6.2	Other Alternatives	124
5	Power and Sample Size Determination	127
5.1	Introduction	127
5.2	Hypotheses and Type I and Type II Errors	128
5.2.1	Hypotheses Testing	128
5.2.2	Type I and Type II Errors	129
5.2.3	Hypotheses Setting	130
5.3	Power and Relative Efficiency	134
5.3.1	Power and Size of Tests	134
5.3.2	Power of Schuirmann's Two One-Sided t Tests Procedure	135
5.3.3	Power of Anderson and Hauck's Test Procedure	140
5.3.4	Power Approach for Assessing Average Bioequivalence	142
5.3.5	Relative Efficiency	145
5.4	Sample Size Determination	151
5.4.1	Sample Size for Point Hypotheses	153
5.4.2	Sample Size for Interval Hypotheses	154
6	Transformation and Analysis of Individual Subject Ratios	161
6.1	Introduction	161
6.2	Multiplicative (or Log-Transformed) Model	162
6.3	Bioequivalence Measures	163
6.4	Maximum Likelihood Estimator	165
6.5	Minimum Variance Unbiased Estimator	168
6.6	Mean of Individual Subject Ratios	170
6.7	Ratio of Formulation Means	172
6.8	Comparison of MLE, MVUE, MIR, and RM	175
6.9	Example	180
6.9.1	Maximum Likelihood Estimator $\hat{\delta}_{ML}$	182
6.9.2	Minimum Variance Unbiased Estimator $\hat{\delta}_{MVUE}$	183
6.9.3	Mean of Individual Subject Ratios $\hat{\delta}_{MIR}$	183
6.9.4	Ratio of Formulation Means $\hat{\delta}_{RM}$	184
6.10	Discussion	185

7	Assessment of Inter- and Intra-Subject Variabilities	187
7.1	Introduction	187
7.2	Variability and Decision Making.....	188
7.3	Point and Interval Estimates	190
7.3.1	Point Estimates.....	190
7.3.2	Confidence Intervals.....	192
7.4	Tests for Equality of Variabilities.....	195
7.4.1	Pitman–Morgan’s Adjusted F Test	196
7.4.2	Distribution-Free Test Based on Spearman’s Rank Correlation Coefficient	200
7.4.3	Tests in the Presence of Period Effects	201
7.5	Equivalence in Variability of Bioavailability	204
7.6	CV Assessment	212
7.6.1	Conditional One-Way Random Effects Model.....	212
7.6.2	Estimators for the Common CV	214
7.7	Discussion	216
8	Assumptions of Outlier Detection for Average Bioequivalence	221
8.1	Introduction.....	221
8.1.1	Model Selection	221
8.1.2	Drug Safety and Exchangeability	222
8.1.3	Outlying Data.....	222
8.2	Tests for Assumptions	222
8.2.1	Intra-Subject Residuals	223
8.2.2	Inter-Subject Residuals	225
8.3	Definition of Outlying Observations	235
8.4	Detection of Outlying Subjects.....	238
8.4.1	Likelihood Distance and Estimates Distance.....	238
8.4.2	Hotelling T^2	240
8.5	Detection of Outlying Observations	247
8.5.1	Residual Approaches.....	247
8.5.2	Mean-Shift Model	253
8.6	Discussion	254
9	Optimal Crossover Designs for Two Formulations for Average Bioequivalence	257
9.1	Introduction.....	257
9.2	Balaam’s Design	258
9.2.1	Analysis of Average Bioavailability	260
9.2.2	Inference for the Carryover Effect.....	262
9.2.3	Assessment of Intra-Subject Variabilities	263
9.3	Two-Sequence Dual Design	266
9.3.1	Analysis of Average Bioavailability	268
9.3.2	Inference for the Carryover Effect.....	269
9.3.3	Intra-Subject Contrasts	270
9.3.4	Assessment of Intra-Subject Variabilities	272

9.4	Optimal Four-Period Designs	276
9.4.1	Two-Sequence, Four-Period Design	276
9.4.2	Four-Sequence, Four-Period Design	284
9.5	Transformation and Individual Subject Ratios	287
9.5.1	Balaam's Design	287
9.5.2	Two-Sequence Dual Design	288
9.5.3	Four-Sequence, Four-Period Design	289
9.6	Sample Size for Higher-Order Crossover Designs	289
9.7	Discussion	293
10	Assessment of Bioequivalence for More Than Two Formulations	301
10.1	Introduction	301
10.2	Assessment of Average Bioavailability with More Than Two Formulations.....	302
10.2.1	Statistical Model and Assumptions.....	302
10.2.2	Confidence Interval and Two One-Sided Tests Procedure.....	304
10.2.3	Log-Transformation	305
10.2.4	Variance-Balanced Designs	305
10.3	Analyses for Williams Designs.....	307
10.3.1	Williams Designs with Three Formulations	307
10.3.2	Williams Design with Four Formulations	312
10.3.3	Heterogeneity of Intra-Subject Variabilities	322
10.4	Analysis for Balanced Incomplete Block Design.....	326
10.5	Discussion	328
III	Population and Individual Bioequivalence	333
11	Population and Individual Bioequivalence	335
11.1	Introduction	335
11.2	Limitation of Average Bioequivalence.....	337
11.3	Merits of Individual Bioequivalence and Desirable Features of Bioequivalence Criteria	343
11.4	Measures of Discrepancy	346
11.5	Probability-Based Criteria.....	348
11.6	Moment-Based Criteria.....	351
11.7	Relations among Criteria	356
11.8	Bioequivalence Limits	361
11.9	Designs for Population and Individual Bioequivalence	364
11.10	Discussion	368
12	Statistical Procedures for Assessment of Population and Individual Bioequivalence	377
12.1	Introduction	377
12.2	Estimation Procedures.....	378

12.3	Procedures for Moment-Based Criteria	385
12.3.1	Procedures Based on the Linearized Form of M_{13}	385
12.3.2	Algorithm Based on Disaggregate Criteria.....	396
12.4	Procedures for Probability-Based Criteria	402
12.4.1	Algorithm for TIER	402
12.4.2	Parametric Algorithm for TIER	408
12.4.3	Algorithm Based on Tolerance Interval.....	409
12.4.4	Algorithm for P_d	411
12.5	Generalized p -Values for Evaluation of Population Bioequivalence	415
12.6	Discussion	419

IV In Vitro and Alternative Evaluation of Bioequivalence 423

13	Assessment of Bioequivalence for Drugs with Negligible Plasma Levels	425
13.1	Introduction	425
13.2	Design and Clinical Endpoints	425
13.3	Statistical Considerations	427
13.3.1	Continuous Endpoint	427
13.3.2	Binary Endpoint	428
13.4	WLS Method.....	431
13.5	Log-Linear Models.....	439
13.6	Generalized Estimating Equations	442
13.7	Analysis of Time to Onset of a Therapeutic Response	446
13.8	Discussion	449
14	In Vitro Bioequivalence Testing	451
14.1	Introduction	451
14.2	Study Design and Data Collection	452
14.2.1	Study Design.....	452
14.2.2	Emitted Dose Uniformity, Priming/Re-Priming, and Tail-Off Profile	453
14.2.3	Spray Pattern	453
14.2.4	Droplet Size Distribution	453
14.2.5	Plume Geometry	454
14.3	Bioequivalence Limit.....	454
14.4	Statistical Methods.....	455
14.4.1	Noncomparative Analysis	456
14.4.2	Nonprofile Analysis	456
14.4.3	Profile Analysis	458
14.5	Example	460
14.5.1	Study Design.....	460